According to Chamelin’s grant application, the church plans to spend $1,500 to buy the livestock, $375 to butcher, process ...

Drug regulatory agencies in Germany and Australia have added warnings that atomoxetine can trigger violent or suicidal thoughts—sparking urgent concern over its long‑term use in children and adults.

Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of GLP-1/amylin agonist amycretin that achieved reductions of between 10.4% and 13.1% in ...

Yet, within the past 24 hours, Trump has doubled the tariffs on India to 50%, imposed an additional 15% on Japan, announced a ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

CNBC’s Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk Box' to discuss the company's quarterly earnings results, late-stage trial data on its experimental obesity pill ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

Eli Lilly says a first-of-its-kind weight-loss pill could be on pharmacy shelves by next year after a successful phase 3 ...